Introduction {#s1}
============

Recent strategies to produce mouse lines that contain large genomic rearrangements represent a major advance to accelerate functional genomics and to provide animal models for developmental processes and human diseases such as contiguous gene and gene dosage effect syndromes. The first chromosomal rearrangements were obtained in the mouse using X-ray irradiation \[[@pgen-0020086-b001]\] or chemicals \[[@pgen-0020086-b002]\]. However, the size and position of the induced rearrangements cannot be predetermined even though the use of specific selectable markers and embryonic stem (ES) cells has improved the irradiation strategy, making it possible to generate a series of interstitial deletions at a given locus \[[@pgen-0020086-b003]--[@pgen-0020086-b006]\]. Homologous recombination in ES cells using replacement vectors has generated deletion of genomic fragments up to 30 kb \[[@pgen-0020086-b007],[@pgen-0020086-b008]\], but inducing large defined chromosomal rearrangements was only achieved in the mid-1990s by taking advantages of the Cre/*loxP* recombinase system \[[@pgen-0020086-b009]--[@pgen-0020086-b012]\] and defining the chromosomal engineering strategy.

This technology led to the creation of new genetic tools for functional analysis of the mouse genome. Generation of deletions with engineered visible markers provides segmental haploidy to study recessive mutations \[[@pgen-0020086-b010],[@pgen-0020086-b013]\], whereas inversions can serve as balancer chromosomes to prevent crossing-over and to facilitate large-scale mutagenesis screens for recessive lethal mutations \[[@pgen-0020086-b014],[@pgen-0020086-b015]\]. The possibility of manipulating large chromosome fragments or whole chromosomes using microcell-mediated chromosome transfer (MMCT) offers the opportunity to study the function of large genes or clusters of genes and provides more and more mouse models to study human pathologies such as contiguous gene syndromes. In this review, we describe the panel of techniques available for chromosome engineering in the mouse, some of their applications for studying gene function and genomic organization and for modeling human diseases, and the implications for future research.

Chemical and Radiation-Induced Chromosome Rearrangements {#s2}
========================================================

Historically, various types of rearrangements including deletions, inversions, and reciprocal translocations were obtained through irradiation or chemical mutagenesis. Such chromosomal configurations are important tools for looking at recessive lethal mutations in mice \[[@pgen-0020086-b016]\] or to obtain mouse models of partial aneuploidy. For example, Ts65Dn is a well-known model to study human trisomy 21 that recapitulates several phenotypic features of people with Down syndrome \[[@pgen-0020086-b017],[@pgen-0020086-b018]\].

A major improvement of the radiation strategy was developed to induce a panel of deletions at a defined region \[[@pgen-0020086-b005]\]. Starting from the integration of a negative selection marker such as the *tk* gene into a predetermined locus by homologous recombination in a hybrid ES cell line, You et al. \[[@pgen-0020086-b005],[@pgen-0020086-b019]\] were able to select for the loss of the negative marker after irradiation. The characterization of the deletions is then achieved by taking advantage of genetic markers that are polymorphic in the hybrid ES cells ([Figure 1](#pgen-0020086-g001){ref-type="fig"}). Using this approach, Schimenti et al. \[[@pgen-0020086-b003]\] generated three overlapping deletion complexes spanning about 40 cM of mouse chromosome 5 (MMU5), allowing the systematic characterization of the functional regions of this chromosome by pairwise combination of the deletions through mating and serving as a model of the Wolf-Hirschhorn contiguous gene syndrome that resides in this region \[[@pgen-0020086-b003],[@pgen-0020086-b020]\].

![Generation and Characterization of Radiation-Induced Deletion Complexes in Mouse ES Cells\
(A) Insertion of a negative selectable marker (cassette Neo-tk: Hsv-thymidine kinase/neomycin resistance) into a predetermined locus by homologous recombination in F1 hybrid (129/SvJae x C57BL/6J) ES cells (C57BL/6J chromosome represented with a black centromere; 129/SvJae chromosome represented with a white centromere).\
(B) Treatment of the neomycin-resistant targeted cells with radiation to induce the deletions.\
(C) Selection in medium containing 1,2′-deoxy-2′-fluoro-β-D-arabinofuranosyl-5-iodouracil of the colonies having lost the *tk* gene.\
(D) Characterization of the deletion breakpoints by amplification of the DNA from these clones using primers corresponding to genetic polymorphic markers (represented under the chromosome map by letters a--j) flanking the site of the targeted integration. Deletions are represented as solid boxes.](pgen.0020086.g001){#pgen-0020086-g001}

Using Site-Specific Recombinase to Generate Megabase Chromosome Rearrangements {#s3}
==============================================================================

 {#s1a}

### In vitro. {#s1a1}

More defined rearrangements require the use of the Cre/*loxP* technology in mouse ES cells \[[@pgen-0020086-b009]--[@pgen-0020086-b011]\]. By two consecutive events one can target the *loxP* sites to predefined loci in the genome by homologous recombination. Expression of the Cre recombinase induces the desired rearrangement through site-specific recombination between the two *loxP* sites, depending on their relative position and orientation ([Figure 2](#pgen-0020086-g002){ref-type="fig"}). For small regions (less than 100 kb), deletions and inversions can be easily generated, starting from ES cells carrying two *loxP* sites inserted in a *cis* configuration, that are treated with Cre recombinase \[[@pgen-0020086-b021],[@pgen-0020086-b022]\]. However, the rearrangement occurs at a lower efficiency for larger regions. Thus, targeting vectors containing the 5′ or 3′ part of a positive selection cassette with *loxP* located downstream or upstream, respectively, were designed. Expression of the Cre recombinase results in the desired rearrangement through site-specific recombination between the two *loxP* sites, enabling the selection of the recombined allele through the restoration of the selection marker upon rearrangement. Different markers such as *Hprt* \[[@pgen-0020086-b010]\] or the resistance genes for neomycin \[[@pgen-0020086-b023]\], puromycin \[[@pgen-0020086-b024],[@pgen-0020086-b025]\], or hygromycin \[[@pgen-0020086-b026]\] were used. As an alternative, a *tk* negative selection marker can be deleted in the rearranged locus \[[@pgen-0020086-b027]--[@pgen-0020086-b030]\].

![The Different Types of Chromosomal Rearrangements Produced by the Cre/*loxP* Recombinase System\
Deletions, duplications, or inversions can be produced depending on the relative orientation of the *loxP* sites, on their position on the homologous chromosome (i.e., in *cis* or in *trans*), and on the cell cycle stage during which the Cre-mediated recombination occurs (G1 or G2).\
(A) Recombination between *loxP* sites (green arrowhead) integrated in the same orientation in a *cis* configuration during the G1 phase can only generate a deletion of the region of interest (red arrow); the same configuration in the G2 phase can result in the creation of a deletion and a duplication.\
(B) The deletion and the corresponding duplication can also be obtained from a *trans* configuration in both G1 and G2 phases. This represents the best configuration to establish the deleted and duplicated chromosomes in the mouse, with both chromosomes compensating for each other with regard to genetic dosage, thus reducing the potential consequence of haploinsufficiency.\
(C and D) When the *loxP* sites are oriented in opposite directions in a *cis* configuration, an equilibrium with two forms, inverted and non-inverted, is obtained if the Cre is expressed in G1, while a more likely unstable recombined pair of acentric and dicentric chromosomes is generated if Cre reacts on *loxP* sites after the S phase or from a *trans* configuration. From all these recombinant alleles, only those containing the reconstituted mini-gene, however, will be retained during the selection in vitro. Recombinant ES-cell clones should be extensively characterized to verify the engineered chromosome (by Southern blot analysis, normal and quantitative PCR, or FISH).\
Del, deletion; Dup, duplication; Inv, inversion; Rec, one of the original recombinant alleles.](pgen.0020086.g002){#pgen-0020086-g002}

The efficiency of the in vitro technique, and hence its feasibility, depends on the chromosomal context and more dramatically on the design of the experiment \[[@pgen-0020086-b031]--[@pgen-0020086-b034]\]. Cre-mediated recombination efficiency is dependent on different factors such as the increasing distance between the *loxP* sites for a *cis* configuration (10% to 0.1% efficiency), the level of recombinase activity, and the region of interest that could induce ES-cell lethality after deletion \[[@pgen-0020086-b010],[@pgen-0020086-b031],[@pgen-0020086-b032],[@pgen-0020086-b035]\] (unpublished data). Increasing the efficiency of the technique by a factor of 10 can be achieved by using a GFP/Cre expressing vector or classical co-transfection, followed by fluorescent-activated cell sorting of GFP+ cells that also express Cre \[[@pgen-0020086-b036],[@pgen-0020086-b037]\].

Another dimension of the chromosomal engineering in vitro is the induction of mitotic recombination in G2 phase to produce selectable homozygous daughter cells from a double heterozygous mother for genetic mosaics. Such a powerful method can selectively produce ES-cell clones carrying homozygous mutations for functional recessive mutations screens in vitro, speeding up the analysis of a gene\'s function in cells \[[@pgen-0020086-b038],[@pgen-0020086-b039]\].

Using the in vitro technique requires two targeting vectors for each bordering loci that could contain different types of selectable cassettes for inducing and selecting chromosomal rearrangements in various types of ES cells. But in the case of the restoration of the HPRT function, the use of *Hprt*-deficient ES cells such as AB2.2 \[[@pgen-0020086-b010]\] or HM-1 \[[@pgen-0020086-b040]\] is required. Nevertheless, this is a method of choice given the number of ready-to-use targeting vectors for the *Hprt* selection system available from the Mutagenic Insertion and Chromosome Engineering Resource \[[@pgen-0020086-b041]\] (MICER; http://www.sanger.ac.uk/micer/), the use of retroviral vectors to target the second *loxP* site \[[@pgen-0020086-b042]--[@pgen-0020086-b044]\], and the panel of rearranged chromosomes that has been engineered \[[@pgen-0020086-b015],[@pgen-0020086-b041]\]. Furthermore, the presence of coat color markers in those targeting vectors allows an easy discrimination of mice carrying the recombined chromosome \[[@pgen-0020086-b013]\].

The in vitro strategy was developed extensively to study specific loci containing large genes or clusters of genes (see [Table 1](#pgen-0020086-t001){ref-type="table"}) \[10,21,22,25--28,45--56\], to generate translocations or deletions similar to those found in cancer \[9,11,30--32,57--62\], or to create models of contiguous gene syndromes, such as the Smith-Magenis \[[@pgen-0020086-b044],[@pgen-0020086-b063]--[@pgen-0020086-b066]\], Prader-Willy \[[@pgen-0020086-b067]\], and DiGeorge syndromes \[[@pgen-0020086-b043],[@pgen-0020086-b068],[@pgen-0020086-b069]\]. Similarly, new mouse models of Down syndrome have been generated to study the impact of a critical region identified in human Chromosome 21 \[[@pgen-0020086-b023]\]. Taken together, these data illustrate how large-scale chromosomal engineering is a powerful tool to unravel genes with dosage effects and their contribution to aneuploid syndromes in the mouse model.

###### 

Genomic Rearrangements Induced in the Mouse Genome by Chromosome Engineering

![](pgen.0020086.t001)

Unraveling lethal mutations is difficult in classical mutagenesis screens, unless a chromosome carrying an inversion is used as a balancer chromosome \[[@pgen-0020086-b015]\]. The production of inversions by chromosome engineering in the mouse offers the advantage of controlling the size of the inverted region and of generating inversions that will induce lethality in homozygous state, such as those obtained on mouse Chromosome 11 that disrupt the *Wnt3* gene \[[@pgen-0020086-b014],[@pgen-0020086-b031],[@pgen-0020086-b032],[@pgen-0020086-b070]\] or on Chromosome 4 \[[@pgen-0020086-b071]\]. Using such a balancer chromosome approach associated with chemical mutagenesis, two mutagenesis screens led to the characterization of, respectively, 59 recessive lethal mutations on mouse Chromosome 11, and 19 mutations on mouse Chromosome 4 \[[@pgen-0020086-b014],[@pgen-0020086-b072]\].

### In vivo. {#s3X0X2}

Cre-mediated recombination is widely used to generate conditional mutagenesis for a gene of interest in a tissue- or time-dependent manner \[[@pgen-0020086-b073]\]. Similarly, several groups succeeded in generating in vivo large deletions, duplications, inversions, and translocations ([Table 1](#pgen-0020086-t001){ref-type="table"}). This can be carried out between two *loxP* sites in *cis* either inserted in ES cells \[[@pgen-0020086-b022],[@pgen-0020086-b074]--[@pgen-0020086-b076]\] or selected after classical crossing-over between two original founder lines by the sequential targeted recombination induced genomic rearrangement (STRING) ([Figure 3](#pgen-0020086-g003){ref-type="fig"}), \[[@pgen-0020086-b024],[@pgen-0020086-b077],[@pgen-0020086-b078]\]. Furthermore, the targeted meiotic recombination (TAMERE) strategy allows to obtain both a deletion and a duplication of a region of up to 150 kb, starting from two *loxP* sites, in a *trans* configuration, with a frequency that can vary from 1% to 10% ([Figure 3](#pgen-0020086-g003){ref-type="fig"}) \[[@pgen-0020086-b012],[@pgen-0020086-b079]\]. Similarly to in vitro, the recombination frequency decreases in vivo for large regions. Nevertheless it is still effective for *cis* configuration (0.3%--1%) separated by up to 28 Mb \[[@pgen-0020086-b078]\], but seems to be not workable with *loxP* in *trans* distant from 3.9 Mb \[[@pgen-0020086-b034]\]. Thus, the STRING approach \[[@pgen-0020086-b078]\] offers an interesting alternative to the MICER strategy, without the need for extensive technological investments, but still requires an efficient and large genotyping program.

![Strategies for In Vivo Cre-Mediated Recombination\
(A) The general principle of TAMERE is based on two successive breedings in order to have in one male, named the trans-loxer, the *Sycp1Cre* (*Synaptonemal Complex protein 1*) transgene and the two *loxP* sites in a *trans* configuration, inserted previously in the same orientation at each targeted locus, that define the genetic interval. The *Synaptonemal Complex protein 1* promoter drives Cre expression at prophase of meiosis in male spermatocytes when chromatid pairs are closely aligned, in order to facilitate the chromatid exchange, leading to the formation of the deletion and the duplication of the interval delimited by the two *loxP* sites. The last step consists in mating trans-loxer males with wild-type females to generate, in the progeny, individuals carrying the deletion or the duplication of the targeted region.\
(B) The STRING approach takes advantage of a classical crossing-over to bring the two *loxP* sites into a *cis* configuration to generate a deletion. Two parental mice (F~0~) carrying *loxP* sites flanking a selected region are crossed. The F~1~ progeny containing the two *loxP* sites are then mated to wild-type mice. The offspring are screened for meiotic crossing-over between both sites leading to mice carrying the *loxP* sites in a *cis* configuration. In the subsequent cross, a ubiquitously expressed Cre transgene is introduced, generating the deletion that is established in the next F~4~ generation.\
Del, deletion; Dup, duplication.\
red arrow, region of interest; green arrow, *loxP* site.](pgen.0020086.g003){#pgen-0020086-g003}

In vivo chromosomal engineering during mitosis often leads to mosaic individuals in the first progeny in which the *Cre* transgene is combined with *loxP* sites in *cis* \[[@pgen-0020086-b074],[@pgen-0020086-b080]\]. The level of mosaicism found depends on a balance between the size of the targeted region and Cre activity. For example, Mersher et al. (2001) noticed 17% of mosaic mice for a 1.5-Mb deletion using the *ZP3-Cre* line expressed in the oocytes, and we found 26% of mice showing a mosaic profile for a 0.7-Mb induced deletion using a *CMV-Cre* expressing line \[[@pgen-0020086-b081]\]. Genetic mosaicism could be an advantage for lineage analysis as Cre-induced rearrangements can be used to label and trace a cell population in vivo \[[@pgen-0020086-b082]\]. Thus, it is crucial to well characterize the Cre transgenic lines, by analyzing the expression of Cre mRNA, or the Cre activity by mating with a mouse carrying a reporter gene such as the R26R \[[@pgen-0020086-b083]\] and ACZL lines \[[@pgen-0020086-b084]\].

Large rearrangements can lead to early embryonic lethality. Hence, absence of mice carrying the new engineered chromosome in the in vivo approach could be caused by a failure of Cre-mediated recombination but could also depend on the lethal effect of the new genetic configuration \[[@pgen-0020086-b085]\]. To address such questions, it is important to test for the presence of the new chromosomal configuration in the carrier double-transgenic animal \[[@pgen-0020086-b078]\]. An alternative would be to compensate the deletion with a balanced duplication \[[@pgen-0020086-b085]\]. Unfortunately, an efficient strategy needs to be explored to induce such *trans* recombination in vivo for large regions. An additional way to overcome this problem is to trigger the recombination in a time- and/or tissue-specific manner, but only a few reports so far have described this option \[[@pgen-0020086-b031],[@pgen-0020086-b061],[@pgen-0020086-b062]\].

In vivo approaches to making deletions and inversions were largely used to explore the function and regulation of genes ([Table 1](#pgen-0020086-t001){ref-type="table"}). The best example for such studies is the extensive work done over the last ten years by D. Duboule and collaborators to analyze the molecular mechanisms that modulate expression of *Hox* genes encoding transcription factors controlling positional information along the trunk and limb axes \[22,45,46,76,86--88\]. In particular, they have combined the in vivo strategy with knock-in of a *lacZ* reporter gene, to trace the consequences of the induced rearrangements on the expression of the *Hoxd* genes during embryonic development. Similar deletion approaches were used to study *cadherin 1* gene regulation \[[@pgen-0020086-b075]\]. Herault et al. \[[@pgen-0020086-b089]\] extended this strategy by replacing the *LacZ* by the *Cre* to provide a tool to specifically inactivate *Hox* genes in progressively more extended domains of *Hox* expression. On the whole, the in vivo strategy appears very attractive as it is less expensive, doesn\'t need the settling of a large breeding program, and avoids a few complicated steps of cell culturing thanks to the increasing availability of mouse or ES cell lines containing *loxP* sites ([Table 2](#pgen-0020086-t002){ref-type="table"}).

###### 

Resources Available Online for Chromosomal Engineering in Mice

![](pgen.0020086.t002)

The mosaic analysis with double markers \[[@pgen-0020086-b082]\] combines chimeric fluorescent constructs and G2-induced mitotic recombination in vivo. Such a strategy allows determination of the consequence of mutation by visualization of double-colored mutated cells, enabling high-resolution lineage tracing in vivo to elucidate biological processes, such as cell fate in the nervous system. The development of such a strategy will lead to genetic mosaic analysis, bypassing the problem of the lethality linked to some mutations by exploring the mosaic condition.

Transchromosomal Lines {#s4}
======================

The Cre/*loxP* system allows the modeling of native chromosomes while MMCT enables manipulation of large fragments or whole chromosomes from various species and particularly human with the making of transchromosomic lines. This technique originally developed in the 1970s, is based on the fusion of microcells, containing single or small numbers of chromosomes, with whole cells in order to transfer exogenous chromosome material into host cells (for a review, see \[[@pgen-0020086-b090],[@pgen-0020086-b091]\]). MMCT can be carried out with somatic cells, embryonic carcinoma cells or ES cells as recipients. Applications of MMCT are numerous, ranging from hunting for tumor suppressor, DNA repair or senescence-inducing genes, assessing genomic instability, imprinting and chromatin modification, constructing and manipulating artificial chromosomes for potential gene therapies to act as vectors for specific genes or genomic regions, and expressing proteins or studying aspects of chromosome behaviour in mitosis and meiosis \[[@pgen-0020086-b092]--[@pgen-0020086-b095]\].

A further application is the creation of mouse lines that carry fragments or whole human chromosomes as freely segregating extra chromosomes. To achieve this, transchromosomic mouse ES cells were injected into mouse blastocysts to produce mouse chimeras. The first transchromosomal animals were produced in the late 1990s and carried different human chromosome fragments as freely segregating extra chromosomes \[[@pgen-0020086-b096]\]. Using this technique, models of Down syndrome were obtained in chimeric mice with transchromosomal ES cells containing different parts of human Chromosome 21 (Hsa21), ranging from \~50 to \~0.2 Mb \[97.98\]. But the chromosome fragments tended to be lost during development, leading to phenotypic variations. In spite of this, the chimeric animals exhibited behavioral impairments and cardiac defects similar to those described in humans with Down syndrome \[[@pgen-0020086-b099],[@pgen-0020086-b100]\]. E. Fisher and collaborators succeeded in producing a trans-species aneuploid mouse line, called Tc1, that stably transmitted almost a complete Hsa21, generating a more full model of Down syndrome \[[@pgen-0020086-b101]\]. Indeed, the Tc1 line displays a large set of deficits similar to those observed in trisomic 21 patients that were not found in earlier models. The previously observed failure of transchromosomal germline transmission was overcame by using female mouse ES cell lines to derive female chimeras that support the transmission of the aneuploid chromosome through the germline \[[@pgen-0020086-b097]\]. Nevertheless such transchromosomic lines are difficult to obtain and to work with. A large number of ES cell clones should be controlled to detect any rearrangements and should be injected to recover a germline transmission. In addition, transmission from Tc1 females only could be achieved with a rate of 40% in a hybrid genetic background, and a large panel of animals should be studied as the aneuploid chromosome tends to be lost during mitosis with variable rates \[[@pgen-0020086-b101]\]. Nonetheless, transchromosomic lines offer a promising substitute to mouse segmental aneuploidies, as the complete genomic sequence is included, and hence modeling a more complete human aneuploidy.

Conclusion {#s5}
==========

Chromosome engineering combined with the transchromosomic approach is widely used for dissecting the function, the regulation, and the contribution of genes to genetic disorders, such as contiguous gene and aneuploidy syndromes. For example, the increasing number of mouse models for trisomy 21 that have been created recently \[[@pgen-0020086-b101],[@pgen-0020086-b102]\] provides the necessary tools to understand how dosage imbalance results in the abnormal phenotypes observed in the human patients. Breeding of the different mouse strains carrying either the duplication or the deletion of human Chromosome 21 syntenic regions will not only allow the creation of a full model for human trisomy 21, but also the deciphering of genetic interaction between regions and enable one to look for candidate genes for each phenotype. This approach is also valid for evaluating the effect of copy number variation of genomic regions observed in the human population that might contribute to the susceptibility to certain diseases \[[@pgen-0020086-b103]--[@pgen-0020086-b105]\]. Manipulating chromosomes on a large scale is likely to be increasingly developed in the future also to identify genes underlying complex phenotypes of polygenic diseases such as diabetes, cancer, asthma, or obesity caused by a combination of environmental and multiple genetic factors. To this end, transchromosomic lines combined with deletions might be a promising way to obtain more humanized models to study specific human genes and pathologies.

Even though both techniques still require considerable effort, they benefit from the development of the MICER resource, with more than 18,000 targeting vectors referenced in the mouse genome database, the increasing number of mouse carrying *loxP* sites at various loci and of Cre transgenic lines ([Table 2](#pgen-0020086-t002){ref-type="table"}). Together with the in vivo approaches TAMERE and STRING \[[@pgen-0020086-b012],[@pgen-0020086-b078]\], any laboratory can now manipulate large genomic regions without any additional work on ES cells, in order to analyze further the genomic organization or to derive new tools for genetic analysis (deletion, duplication, and inversion). These different technologies are further supported by the combined effort of the scientific community to establish large-scale gene trap mutagenesis programs, integrating Cre/*loxP* technology and offering the possibility to create a variety of alleles \[[@pgen-0020086-b106]--[@pgen-0020086-b108]\].

Emerging from these strategies of chromosome engineering is the fascinating aspect of chromosome organization, structure, and function, implicated in the as yet poorly understood code for genetic instructions. Indeed, the human genome contains about 2% of coding sequence, RNA genes, and regulatory regions. In some cases, control regions lay at a great distance from the gene, and hence the long-range interaction is only detected by manipulation of large chromosomal regions \[[@pgen-0020086-b109]--[@pgen-0020086-b112]\]. Surprisingly, a significant amount of the non-coding portion of the genome is under active selection, suggesting that it is also functionally important, yet little is known about it \[[@pgen-0020086-b113]--[@pgen-0020086-b116]\]. Large desert gene regions also are found and are starting to be investigated by using chromosome engineering \[[@pgen-0020086-b030]\]. We speculate that the modeling of chromosome will be more commonly used to better understand the role of non-coding sequences, and may be used to decipher the "C-value enigma" \[[@pgen-0020086-b117]\] and the chromosome architecture lying at the heart of genetic instructions. Our increased ability to manipulate the mammalian genome provides us with new tools for the development of a functional chromoso--genomic approach, bringing an exciting new dimension into biological and biomedical research.

Supporting Information {#s6}
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The accession numbers of genes mentioned in this paper from the GenBank database (<http://www.ncbi.nlm.nih.gov/entrez>) are *Wnt3* gene (NM_009521.1) and *cadherin 1* (NM_009864.1).
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